Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
US H 1526 Medicare Hereditary Cancer USH2369 In Vitro Tests US S 765 Hereditary Cancer Genetic Testing Pharmacogenomic testing, insurance coverage opportunities for whole exome sequencing and specific testing for genetic diseases, opportunities to use genetic testing to justify insurance coverage for specific treatments
US H 1526 Medicare Hereditary Cancer USH2369 In Vitro Tests US S 765 Hereditary Cancer Genetic Testing Pharmacogenomic testing, insurance coverage opportunities for whole exome sequencing and specific testing for genetic diseases, opportunities to use genetic testing to justify insurance coverage for specific treatments
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
2024 · fourth_quarter · 4T
US H 1526 Medicare Hereditary Cancer USH2369 In Vitro Tests US S 765 Hereditary Cancer Genetic Testing Pharmacogenomic testing, insurance coverage opportunities for whole exome sequencing and specific testing for genetic diseases, opportunities to use genetic testing to justify insurance coverage for specific treatments
Veteran access to genetic testing, updating electronic health records for VAMCs.
Source: Senate LDA
US H 1526 Medicare Hereditary Cancer USH2369 In Vitro Tests US S 765 Hereditary Cancer Genetic Testing Pharmacogenomic testing, insurance coverage opportunities for whole exome sequencing and specific testing for genetic diseases, opportunities to use genetic testing to justify insurance coverage for specific treatments
US H 1526 Medicare Hereditary Cancer USH2369 In Vitro Tests US S 765 Hereditary Cancer Genetic Testing Pharmacogenomic testing, insurance coverage opportunities for whole exome sequencing and specific testing for genetic diseases, opportunities to use genetic testing to justify insurance coverage for specific treatments
HR 812 Inflation Reduction Act, including Defense Health, Viral Surveillance funding, COVID Supplemental allocations And funding needs, reauthorization for the ability for certain agencies to pull appropriations and enter into contracts in relation to the Pandemic & All Hazards Preparedness Act Discussion Drafts, including wastewater surveillance, viral surveillance and sequencing, data modernization, Center for Forecasting and Analytics, ASPR
HR 812 Inflation Reduction Act, including Defense Health, Viral Surveillance funding, COVID Supplemental allocations Consolidated Appropriations Act 2023 and affiliated draft bills, HHS funding, ASPR, AMD
A bill to improve outcomes for Medicaid beneficiaries with major depressive disorder or other mental health conditions.
Client: HELIX, INC. · Firm: HELIX, INC.
Viral sequencing derived from blood and spital, viral surveillance and COVID-19 not limited to issues in US H1425 Senate Ratification of Pandemic World Health Organization Agreements, planning for FY24 budget, and Pandemic All Hazards Preparedness Reauthorization. Issues related to biomarker testing, hereditary cancers, and pharmacogenomics including US S708 Medicaid Coverage for Major Depressive Disorders.
US H 1526 Medicare Hereditary Cancer USH2369 In Vitro Tests US S 765 Hereditary Cancer Genetic Testing Pharmacogenomic testing, insurance coverage opportunities for whole exome sequencing and specific testing for genetic diseases, opportunities to use genetic testing to justify insurance coverage for specific treatments
US H 1526 Medicare Hereditary Cancer USH2369 In Vitro Tests US S 765 Hereditary Cancer Genetic Testing Pharmacogenomic testing, insurance coverage opportunities for whole exome sequencing and specific testing for genetic diseases, opportunities to use genetic testing to justify insurance coverage for specific treatments
Pharmacogenomic testing, insurance coverage opportunities for whole exome sequencing and specific testing for genetic diseases. And the regulation of lab developed tests. US H 1526 Medicare Hereditary Cancer USH2369 In Vitro Tests US S 765 Hereditary Cancer Genetic Testing
US H 1526 Medicare Hereditary Cancer USH2369 In Vitro Tests US S 765 Hereditary Cancer Genetic Testing Pharmacogenomic testing, insurance coverage opportunities for whole exome sequencing and specific testing for genetic diseases, opportunities to use genetic testing to justify insurance coverage for specific treatments
US S 2640 Disease X Act 2023, viral surveillance in general sequencing as it relates to discovery of Disease X, development of medical counter-measures Oversight of Lab Developed Tests, express legislative authority
US S 2640 Disease X Act 2023, viral surveillance in general sequencing as it relates to discovery of Disease X, development of medical counter-measures
US S 2640 Disease X Act 2023, viral surveillance in general sequencing as it relates to discovery of Disease X, development of medical counter-measures Oversight of Lab Developed Tests, express legislative authority
viral and human genomic research, testing,funding and insurance coverage, COVID-19 testing and research, Lab Developed Tests H791 and S236 COVID-19 Variants Data Tracking (viral sequencing and analytic supports) H6584 Clinical Trial Diversity H 7667 Rx Drug and Device User Fee Programs (regulation of Lab Developed Tests) H 4128 VALID Act (regulation of Lab Developed Tests) H 2471 Omnibus (PREVENT Pandemics Act, funding for Advanced Molecular Detection, and VALID Act) S2022 Whole Genome Sequencing Clinic (Whole Exome sequencing)
Human and Viral Genomic research, testing,funding and insurance coverage, pandemic preparedness, viral surveillance, Lab Developed Tests H791 and S236 COVID-19 Variants Data Tracking (viral sequencing and analytic supports) H6584 Clinical Trial Diversity H 7667 Rx Drug and Device User Fee Programs (regulation of Lab Developed Tests) H 4128 VALID Act (regulation of Lab Developed Tests) H 2471 Omnibus (PREVENT Pandemics Act, funding for Advanced Molecular Detection, and VALID Act) S2022 Whole Genome Sequencing Clinic (Whole Exome sequencing)
Human and Viral Genomic research, testing,funding and insurance coverage, pandemic preparedness, viral surveillance, Lab Developed Tests H791 and S236 COVID-19 Variants Data Tracking (viral sequencing and analytic supports) H6584 Clinical Trial Diversity H 7667 Rx Drug and Device User Fee Programs (regulation of Lab Developed Tests) H 4128 VALID Act (regulation of Lab Developed Tests) H 2471 Omnibus (PREVENT Pandemics Act, funding for Advanced Molecular Detection, and VALID Act) S2022 Whole Genome Sequencing Clinic (Whole Exome sequencing)
viral and human genomic research, testing,funding and insurance coverage, COVID-19 testing and research, Lab Developed Tests H791 and S236 COVID-19 Variants Data Tracking (viral sequencing and analytic supports) H6584 Clinical Trial Diversity H 7667 Rx Drug and Device User Fee Programs (regulation of Lab Developed Tests) H 4128 VALID Act (regulation of Lab Developed Tests) H 2471 Omnibus (PREVENT Pandemics Act, funding for Advanced Molecular Detection, and VALID Act) S2022 Whole Genome Sequencing Clinic (Whole Exome sequencing)
viral and human genomic research, testing,funding and insurance coverage, COVID-19 testing and research, Lab Developed Tests H791 and S236 COVID-19 Variants Data Tracking (viral sequencing and analytic supports) H6584 Clinical Trial Diversity H 7667 Rx Drug and Device User Fee Programs (regulation of Lab Developed Tests) H 4128 VALID Act (regulation of Lab Developed Tests) H 2471 Omnibus (PREVENT Pandemics Act, funding for Advanced Molecular Detection, and VALID Act) S2022 Whole Genome Sequencing Clinic (Whole Exome sequencing)
viral and human genomic research, testing,funding and insurance coverage, COVID-19 testing and research, Lab Developed Tests H791 and S236 COVID-19 Variants Data Tracking (viral sequencing and analytic supports) H6584 Clinical Trial Diversity H 7667 Rx Drug and Device User Fee Programs (regulation of Lab Developed Tests) H 4128 VALID Act (regulation of Lab Developed Tests) H 2471 Omnibus (PREVENT Pandemics Act, funding for Advanced Molecular Detection, and VALID Act) S2022 Whole Genome Sequencing Clinic (Whole Exome sequencing)
Human and Viral Genomic research, testing,funding and insurance coverage, pandemic preparedness, viral surveillance, Lab Developed Tests H791 and S236 COVID-19 Variants Data Tracking (viral sequencing and analytic supports) H6584 Clinical Trial Diversity H 7667 Rx Drug and Device User Fee Programs (regulation of Lab Developed Tests) H 4128 VALID Act (regulation of Lab Developed Tests) H 2471 Omnibus (PREVENT Pandemics Act, funding for Advanced Molecular Detection, and VALID Act) S2022 Whole Genome Sequencing Clinic (Whole Exome sequencing)
Genomic research and testing, pandemic preparedness, viral surveillance, regulation of Lab Developed Tests in VALID ACT USH 4128 and PREVENT Act. Also US H 791 COVID-19 Variant Data Tracking, USH 6589 Clinical Trial Diversity. USH 7667 Rx Drug and Device User Fees, US S 236 COVID-19 Variants Program.
Human and Viral Genomic research, testing,funding and insurance coverage, pandemic preparedness, viral surveillance, Lab Developed Tests H791 and S236 COVID-19 Variants Data Tracking (viral sequencing and analytic supports) H6584 Clinical Trial Diversity H 7667 Rx Drug and Device User Fee Programs (regulation of Lab Developed Tests) H 4128 VALID Act (regulation of Lab Developed Tests) H 2471 Omnibus (PREVENT Pandemics Act, funding for Advanced Molecular Detection, and VALID Act) S2022 Whole Genome Sequencing Clinic (Whole Exome sequencing)
Whole Exome Sequencing, DNA screening testing and diagnostics, access to clinical trials
Oversight of Lab Developed Tests, express legislative authority. Expanded access to VAMC genetic and pharmacogemomic testing
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE, Veterans Affairs, Dept of (VA)
2024 · third_quarter · Q3
Veteran Affairs genetic testing programs
Whole Exome Sequencing, DNA screening testing and diagnostics, access to clinical trials
Veteran access to genetic testing, updating electronic health records for VAMCs.
Genetic testing and screening for active duty member of the military.
Oversight of Lab Developed Tests, express legislative authority. Expanded access to VAMC genetic and pharmacogemomic testing
US H 1526 Medicare Hereditary Cancer USH2369 In Vitro Tests US S 765 Hereditary Cancer Genetic Testing Pharmacogenomic testing, insurance coverage opportunities for whole exome sequencing and specific testing for genetic diseases, opportunities to use genetic testing to justify insurance coverage for specific treatments
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE, Veterans Affairs, Dept of (VA)
2024 · second_quarter · Q2
Whole Exome Sequencing, DNA screening testing and diagnostics, access to clinical trials
Continuing Resolutions and FY24 Budget Viral Surveillance funding, COVID Supplemental allocation retention, general HHS funding, including ASPR, AMD programs.
US H 1526 Medicare Hereditary Cancer USH2369 In Vitro Tests US S 765 Hereditary Cancer Genetic Testing Pharmacogenomic testing, insurance coverage opportunities for whole exome sequencing and specific testing for genetic diseases, opportunities to use genetic testing to justify insurance coverage for specific treatments
Oversight of Lab Developed Tests, express legislative authority.
Filing targets: Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
2024 · first_quarter · Q1
US H 1526 Medicare Hereditary Cancer USH2369 In Vitro Tests US S 765 Hereditary Cancer Genetic Testing Pharmacogenomic testing, insurance coverage opportunities for whole exome sequencing and specific testing for genetic diseases, opportunities to use genetic testing to justify insurance coverage for specific treatments
Oversight of Lab Developed Tests, express legislative authority. Viral Surveillance in clinical settings.
Continuing Resolutions and FY24 Budget Viral Surveillance funding, COVID Supplemental allocation retention, general HHS funding, including ASPR, AMD programs
Filing targets: Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2023 · fourth_quarter · Q4
US H 1526 Medicare Hereditary Cancer USH2369 In Vitro Tests US S 765 Hereditary Cancer Genetic Testing Pharmacogenomic testing, insurance coverage opportunities for whole exome sequencing and specific testing for genetic diseases, opportunities to use genetic testing to justify insurance coverage for specific treatments
Continuing Resolutions and FY24 Budget Viral Surveillance funding, COVID Supplemental allocations, general HHS funding, including ASPR, AMD programs
US S 2640 Disease X Act 2023, viral surveillance in general sequencing as it relates to discovery of Disease X, development of medical counter-measures Oversight of Lab Developed Tests, express legislative authority
Filing targets: Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2023 · third_quarter · Q3
HR 812 Inflation Reduction Act, including Defense Health, Viral Surveillance funding, COVID Supplemental allocations Consolidated Appropriations Act 2023 and affiliated draft bills, HHS funding, ASPR, AMD
US H 1526 Medicare Hereditary Cancer USH2369 In Vitro Tests US S 765 Hereditary Cancer Genetic Testing Pharmacogenomic testing, insurance coverage opportunities for whole exome sequencing and specific testing for genetic diseases, opportunities to use genetic testing to justify insurance coverage for specific treatments
US S 2640 Disease X Act 2023, viral surveillance in general sequencing as it relates to discovery of Disease X, development of medical counter-measures Oversight of Lab Developed Tests, express legislative authority
2023 · first_quarter · 1A
COVID-19, other respiratory pathogen sequencing, including a comprehensive early warning network and countermeasure development in relation to Pandemic All Hazards Preparedness Act Reauthorization, express congressional authorization for FDA regulation of lab developed tests.
Funding for viral sequencing (AMD, ASPR), data modernization, Center for Forecasting and Analytics and other non-specific programs to enhance interdepartmental communication on viral surveillance efforts, including considerations in the End the Threat of Default Act US-H415
Biosecurity efforts around viral surveillance and sequencing for known and unknown pathogens, intergovernmental cooperation on pathogens of pandemic potential
2023 · second_quarter · 2A
Pharmacogenomic testing, insurance coverage opportunities for whole exome sequencing and specific testing for genetic diseases. And the regulation of lab developed tests. US H 1526 Medicare Hereditary Cancer USH2369 In Vitro Tests US S 765 Hereditary Cancer Genetic Testing
HR 812 Inflation Reduction Act, including Defense Health, Viral Surveillance funding, COVID Supplemental allocations And funding needs, reauthorization for the ability for certain agencies to pull appropriations and enter into contracts in relation to the Pandemic & All Hazards Preparedness Act Discussion Drafts, including wastewater surveillance, viral surveillance and sequencing, data modernization, Center for Forecasting and Analytics, ASPR
2023 · second_quarter · Q2
COVID-19, Disease X and other respiratory pathogen sequencing and countermeasure development
Viral surveillance and viral sequencing
Biosecurity and identification of unknown pathogens
2023 · first_quarter · Q1
COVID-19 Testing Coverage post pandemic, access to pharmacogenomic testing
Viral surveillance and viral sequencing
Biosecurity and identification of unknown pathogens
2022 · fourth_quarter · 4A
viral and human genomic research, testing,funding and insurance coverage, COVID-19 testing and research, Lab Developed Tests H791 and S236 COVID-19 Variants Data Tracking (viral sequencing and analytic supports) H6584 Clinical Trial Diversity H 7667 Rx Drug and Device User Fee Programs (regulation of Lab Developed Tests) H 4128 VALID Act (regulation of Lab Developed Tests) H 2471 Omnibus (PREVENT Pandemics Act, funding for Advanced Molecular Detection, and VALID Act) S2022 Whole Genome Sequencing Clinic (Whole Exome sequencing)
Human and Viral Genomic research, testing,funding and insurance coverage, pandemic preparedness, viral surveillance, Lab Developed Tests H791 and S236 COVID-19 Variants Data Tracking (viral sequencing and analytic supports) H6584 Clinical Trial Diversity H 7667 Rx Drug and Device User Fee Programs (regulation of Lab Developed Tests) H 4128 VALID Act (regulation of Lab Developed Tests) H 2471 Omnibus (PREVENT Pandemics Act, funding for Advanced Molecular Detection, and VALID Act) S2022 Whole Genome Sequencing Clinic (Whole Exome sequencing)
2022 · third_quarter · 3A
viral and human genomic research, testing,funding and insurance coverage, COVID-19 testing and research surveillance, sequencing and development of medical countermeasures for pathogens of pandemic potential Regulation Lab Developed Tests through VALID Act USH4128
Continued use of Covid Supplemental funding for viral surveillance, sequencing blood and spital samples, and PCR testing
Issues related to Human and Viral Genomic research, testing,funding and insurance coverage for hereditary cancer screening and treatment,opportunities for pharmacogenomic testing, pandemic preparedness, viral surveillance, and regulation of Lab Developed Tests.
2022 · second_quarter · 2A
genomic research and testing, COVID-19 testing,research, and respiratory pathogen sequencing and surveillance, Lab Developed Tests USH 4128
Genomic research and testing, pandemic preparedness, viral surveillance, regulation of Lab Developed Tests in VALID ACT USH 4128 and PREVENT Act. Also US H 791 COVID-19 Variant Data Tracking, USH 6589 Clinical Trial Diversity. USH 7667 Rx Drug and Device User Fees, US S 236 COVID-19 Variants Program.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE, White House Office
2022 · first_quarter · 1A
General issues relating to genomic research and testing, COVID-19 testing and research, viral surveillance and sequencing. Regulation of lab developed tests VALID Act discussion drafts.
Issues relating to Genomic research and testing, pandemic preparedness, viral surveillance and sequencing COVID-19 and other respiratory pathogens. Issues relating to the regulation of Lab Developed Tests including the VALID Act, Issues and funding related to the COVID-19 Public Health Emergency, COVID-19 PCR testing, and viral sequencing of COVID-19.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE, White House Office
2022 · fourth_quarter · Q4
viral and human genomic research, testing,funding and insurance coverage, COVID-19 testing and research, Lab Developed Tests H791 and S236 COVID-19 Variants Data Tracking (viral sequencing and analytic supports) H6584 Clinical Trial Diversity H 7667 Rx Drug and Device User Fee Programs (regulation of Lab Developed Tests) H 4128 VALID Act (regulation of Lab Developed Tests) H 2471 Omnibus (PREVENT Pandemics Act, funding for Advanced Molecular Detection, and VALID Act) S2022 Whole Genome Sequencing Clinic (Whole Exome sequencing)
Covid Supplemental for surveillance and testing H2471 Omnibus (Funding for viral sequencing and surveillance, Advanced Molecular Detection, Public Health Infrastructure)
2022 · third_quarter · Q3
Viral Surveillance, Viral and population genomics
viral and human genomic research, testing,funding and insurance coverage, COVID-19 testing and research, Lab Developed Tests
Human and Viral Genomic research, testing,funding and insurance coverage, pandemic preparedness, viral surveillance, Lab Developed Tests
2022 · second_quarter · Q2
genomic research and testing, COVID-19 testing and research, Lab Developed Tests
Genomic research and testing, pandemic preparedness, viral surveillance, Lab Developed Tests
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE, White House Office
2022 · first_quarter · Q1
genomic research and testing, COVID-19 testing and research
Genomic research and testing, pandemic preparedness, viral surveillance
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE, White House Office
2021 · fourth_quarter · 4A
genomic research and testing, COVID-19 testing and research, development of medical countermeasures for pathogens of pandemic potential
Issues relating to COVID-19 testing, viral sequencing and viral surveillance. Issues related to public health data modernization.
Funding for viral sequencing, pandemic preparedness, data modernization efforts relating to public health, public health laboratories, and COVID-19 vaccines, medication.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
2021 · third_quarter · 3A
Issues relating to genomic research and testing, COVID-19 testing and research/developement of medical counter measures
Issues related to COVID-19 testing, pandemic preparedness, viral sequencing and surveillance, including the development of an early warning system for pathogens of pandemic potential
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
2021 · second_quarter · 2A
Issues related to Human and Viral Genomic research, testing,funding pandemic preparedness, viral surveillance and early warning system for pathogens of pandemic potential
Issues relating to COVID-19 testing and research
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
2021 · fourth_quarter · 4A
Genomic research and testing, pandemic preparedness, viral surveillance
genomic research and testing, COVID-19 testing and research
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE, White House Office
2021 · fourth_quarter · Q4
Genomic research and testing, pandemic preparedness, viral surveillance
genomic research and testing, COVID-19 testing and research
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE, White House Office
2021 · third_quarter · Q3
Genomic research and testing, pandemic preparedness, viral surveillance
genomic research and testing, COVID-19 testing and research
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
2021 · second_quarter · 2A
genomic research and testing, COVID-19 testing and research
Genomic research and testing
Filing targets: Centers For Disease Control & Prevention (CDC)
2021 · second_quarter · RR
Genomic Research, Privacy, Health Care Access
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
Viral sequencing derived from blood and spital, viral surveillance and COVID-19 not limited to issues in US H1425 Senate Ratification of Pandemic World Health Organization Agreements, planning for FY24 budget, and Pandemic All Hazards Preparedness Reauthorization. Issues related to biomarker testing, hereditary cancers, and pharmacogenomics including US S708 Medicaid Coverage for Major Depressive Disorders.
Viral surveillance and viral sequencing, development of medical countermeasure for pathogens of pandemic potential
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE, White House Office
US H 1526 Medicare Hereditary Cancer USH2369 In Vitro Tests US S 765 Hereditary Cancer Genetic Testing Pharmacogenomic testing, insurance coverage opportunities for whole exome sequencing and specific testing for genetic diseases, opportunities to use genetic testing to justify insurance coverage for specific treatments
US S 2640 Disease X Act 2023, viral surveillance in general sequencing as it relates to discovery of Disease X, development of medical counter-measures
Coordination with public health and other entities around biosecurity efforts in viral surveillance and sequencing for known and unknown pathogens, including Disease X, data needed to develop medical countermeasures, and Defense Health funding inclusive of genetic testing.
Filing targets: Centers For Disease Control & Prevention (CDC), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
Funding for viral sequencing and surveillance, including from human blood and spital samples
pharmacogenomic testing, insurance coverage for whole exome sequencing and specific genetic tests
Biosecurity efforts around viral surveillance and sequencing for known and unknown pathogens
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, White House Office
COVID-19, other respiratory pathogen sequencing and countermeasure development
Funding for viral sequencing
Biosecurity efforts around viral surveillance and sequencing for known and unknown pathogens
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, White House Office
Covid Supplemental for surveillance and testing H2471 Omnibus (Funding for viral sequencing and surveillance, Advanced Molecular Detection, Public Health Infrastructure)
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, White House Office
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
Viral Surveillance, Viral and population genomics, Lab Developed Tests H 4128 VALID Act (Regulation of Lab Developed Tests)
Human and Viral Genomic research, testing,funding and insurance coverage, pandemic preparedness, viral surveillance, Lab Developed Tests H791 and S236 COVID-19 Variants Data Tracking (viral sequencing and analytic supports) H6584 Clinical Trial Diversity H 7667 Rx Drug and Device User Fee Programs (regulation of Lab Developed Tests) H 4128 VALID Act (regulation of Lab Developed Tests) H 2471 Omnibus (PREVENT Pandemics Act, funding for Advanced Molecular Detection, and VALID Act) S2022 Whole Genome Sequencing Clinic (Whole Exome sequencing)
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, White House Office
Covid Supplemental for surveillance and testing
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, White House Office